Asciminib, a novel BCR::ABL1 inhibitor, has been approved in patients with chronic myeloid leukemia in chronic phase (CML-CP) at a dose of 40 mg twice daily (b.i.d.). A once-daily (q.d.) dosing regimen could provide greater patient compliance in long-term therapy, potentially improving clinical benefit.

This exposure–response analysis showed comparable efficacy/safety profiles for asciminib at 80 mg q.d. and 40 mg b.i.d. dosing regimens for patients without the T315I mutation.

For patients harboring the T315I mutation, asciminib at 200 mg b.i.d. was effective and safe.